SIENA, SALVATORE
SIENA, SALVATORE
Dipartimento di Oncologia ed Emato-Oncologia
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers
2024 G. Mauri, G. Patelli, L. Roazzi, E. Valtorta, A. Amatu, G. Marrapese, E. Bonazzina, F. Tosi, K. Bencardino, G. Ciarlo, E. Mariella, S. Marsoni, A. Bardelli, E. Bonoldi, A. Sartore-Bianchi, S. Siena
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting
2024 A. Hackshaw, O. Fajardo, U. Dafni, H. Gelderblom, P. Garrido, S. Siena, M.H. Taylor, W. Bordogna, C. Nikolaidis
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
2024 D. Ciardiello, G. Mauri, A. Sartore-Bianchi, S. Siena, M.G. Zampino, N. Fazio, A. Cervantes
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
2024 A. Sogari, E. Rovera, G. Grasso, E. Mariella, N.M. Reilly, S. Lamba, G. Mauri, E. Durinikova, P.P. Vitiello, A. Lorenzato, M. Avolio, E. Piumatti, E. Bonoldi, M.C. Aquilano, S. Arena, A. Sartore-Bianchi, S. Siena, L. Trusolino, M. Donalisio, M. Russo, F. Di Nicolantonio, D. Lembo, A. Bardelli
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
2023 F. Meric-Bernstam, V. Makker, A. Oaknin, D. Oh, S. Banerjee, A. González-Martín, K.H. Jung, I. Ługowska, L. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, Y. Ma, S. Puvvada, N. Shire, J. Lee
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
2023 E. Van Cutsem, M. di Bartolomeo, E. Smyth, I. Chau, H. Park, S. Siena, S. Lonardi, Z.A. Wainberg, J. Ajani, J. Chao, Y. Janjigian, A. Qin, J. Singh, F. Barlaskar, Y. Kawaguchi, G. Ku
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
2023 A. Petrelli, S. Rizzolio, F. Pietrantonio, S.E. Bellomo, M. Benelli, L. De Cecco, D. Romagnoli, E. Berrino, C. Orrù, S. Ribisi, D. Moya-Rull, C. Migliore, D. Conticelli, I.M. Maina, E. Puliga, V. Serra, B. Pellegrino, A. Llop-Guevara, A. Musolino, S. Siena, A. Sartore-Bianchi, M. Prisciandaro, F. Morano, M. Antista, U. Fumagalli, G. De Manzoni, M. Degiuli, G.L. Baiocchi, M.F. Amisano, A. Ferrero, C. Marchiò, S. Corso, S. Giordano
Circulating tumor DNA to drive treatment in metastatic colorectal cancer
2023 G. Patelli, G. Mauri, F. Tosi, A. Amatu, K. Bencardino, E. Bonazzina, E.G. Pizzutilo, F. Villa, G. Calvanese, A.G. Agostara, S. Stabile, S. Ghezzi, G. Crisafulli, F. Di Nicolantonio, S. Marsoni, A. Bardelli, S. Siena, A. Sartore-Bianchi
Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features
2023 E. Berrino, M.C. Aquilano, E. Valtorta, V. Amodio, G. Germano, M. Gusmini, K. Gizzi, E. Fenocchio, A. Sapino, S. Marsoni, A. Sartore-Bianchi, A. Bardelli, S. Siena, E. Bonoldi, C. Marchiò
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
2023 T. Yoshino, M. Di Bartolomeo, K. Raghav, T. Masuishi, F. Loupakis, H. Kawakami, K. Yamaguchi, T. Nishina, Z. Wainberg, E. Elez, J. Rodriguez, M. Fakih, F. Ciardiello, K. Saxena, K. Kobayashi, E. Bako, Y. Okuda, G. Meinhardt, A. Grothey, S. Siena
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer
2023 E. Van Cutsem, R. Yaeger, J. Delord, J. Tabernero, L.L. Siu, M. Ducreux, S. Siena, E. Elez, S. Kasper, T. Zander, N. Steeghs, D. Murphy, M. Edwards, Z.A. Wainberg
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
2023 E.G. Pizzutilo, R. Romanò, L. Roazzi, A.G. Agostara, S. Oresti, A. Zeppellini, L. Giannetta, G. Cerea, D. Signorelli, S. Siena, A. SARTORE BIANCHI
Young-onset colorectal cancer: treatment-related nausea, vomiting and diarrhoea
2023 G. Mauri, M. Pedrani, S. Ghezzi, K. Bencardino, S. Mariano, E. Bonazzina, F. Serra, P. Pedrazzoli, R. Caccialanza, G.M. Cavestro, S. Siena, S. Artale, A. Sartore-Bianchi
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review
2023 C. Vaghi, G. Mauri, A.G. Agostara, G. Patelli, E.G. Pizzutilo, Y. Nakamura, T. Yoshino, S. Siena, A. Sartore-Bianchi
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
2023 J.H. Strickler, A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, C. Wu, A.S. Paulson, J.M. Hubbard, A.L. Coveler, C. Fountzilas, A. Kardosh, P.M. Kasi, H. Lenz, K.K. Ciombor, E. Elez, D.L. Bajor, C. Cremolini, F. Sanchez, M. Stecher, W. Feng, T.S. Bekaii-Saab
Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
2023 G. Mauri, V. Gori, G. Patelli, L. Roazzi, F. Rizzetto, L. De Carlis, A. Mariani, U. Cavallari, E. Prada, T. Cipani, M.C. Aquilano, E. Bonoldi, A. Vanzulli, S. Siena, A. Sartore-Bianchi
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
2022 E. Durinikova, N.M. Reilly, K. Buzo, E. Mariella, R. Chilà, A. Lorenzato, J.M.L. Dias, G. Grasso, F. Pisati, S. Lamba, G. Corti, A. Degasperi, C. Cancelliere, G. Mauri, P. Andrei, M. Linnebacher, S. Marsoni, S. Siena, A. Sartore-Bianchi, S. Nik-Zainal, F. Di Nicolantonio, A. Bardelli, S. Arena
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives
2022 G. Patelli, A. Zeppellini, F. Spina, E. Righetti, S. Stabile, A. Amatu, F. Tosi, S. Ghezzi, S. Siena, A. Sartore-Bianchi
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors
2022 G.D. Demetri, F. De Braud, A. Drilon, S. Siena, M.R. Patel, B.C. Cho, S.V. Liu, M. Ahn, C. Chiu, J.J. Lin, K. Goto, J. Lee, L. Bazhenova, T. John, M. Fakih, S.P. Chawla, R. Dziadziuszko, T. Seto, S. Heinzmann, B. Pitcher, D. Chen, T.R. Wilson, C. Rolfo
Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
2022 G. Mauri, G. Patelli, V. Gori, C. Lauricella, B. Mussolin, A. Amatu, K. Bencardino, F. Tosi, E. Bonazzina, E. Bonoldi, A. Bardelli, S. Siena, A. Sartore-Bianchi